Ectoin Lozenges (EHT02) in the Treatment of Oropharyngeal Allergic Symptoms
Launched by BITOP AG · Jun 4, 2019
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
The immune system of humans can show an overreaction to proteins from the environment (allergic reaction). Triggers of these allergic reactions may be e.g. pollen, dust mites, mold or animal hair. Common allergic symptoms include itchy, stuffy, runny nose, sneezing, itchy and watery eyes and respiratory complaints. Allergen-specific immunotherapy is the only treatment that eliminates the causes of allergic disease. An example of such immunotherapies is the sublingual immunotherapy (SLIT). During SLIT, side effects may occur such as local oropharyngeal reactions, e.g. manifesting as itching,...
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • initiation of a SLIT
- • minimum age of 18 years
- • written consent of the patient
- Exclusion criteria:
- • Surgical Procedures in the mouth and throat region prior to the study
- • patients with known intolerance to one of the substances used
- • pregnant or breast-feeding women
About Bitop Ag
Bitop AG is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions for dermatological and infectious diseases. With a commitment to advancing healthcare through cutting-edge research, Bitop AG specializes in the formulation of novel compounds and the optimization of existing treatments. The company leverages its expertise in pharmacology and biotechnology to conduct rigorous clinical trials, ensuring safety and efficacy while addressing unmet medical needs. Bitop AG is dedicated to improving patient outcomes and enhancing therapeutic options through its collaborative approach and state-of-the-art technology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aachen, , Germany
Bad Schönborn, , Germany
Bochum, , Germany
Bonn, , Germany
Gelsenkirchen, , Germany
Heidelberg, , Germany
Jülich, , Germany
Schorndorf, , Germany
Patients applied
Trial Officials
Andreas Bilstein, Dr.
Study Director
CSO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials